Generation of primary antigen-specific human cytotoxic T lymphocytes in human/mouse radiation chimera.
Severe combined immunodeficient (SCID) mice are increasingly used as hosts for the adoptive transfer of human lymphocytes. Human antibody responses can be obtained in these xenogeneic chimeras, but information about the functionality of the human T cells in SCID mice is limited and controversial. Studies using human peripheral blood lymphocytes (PBL) injected intraperitoneally (IP) into SCID mice (hu-PBL-SCID mice) have shown that human T cells from these chimeras are anergic and have a defective signaling via the T-cell receptor. In addition, their antigenic repertoire is limited to xenoreactive clones. In the present study, we tested the functionality of human T cell in a recently described chimeric model. In this system, BALB/c mice are conditioned by irradiation and then transplanted with SCID bone marrow, followed by IP injection of human PBL. Our experiments demonstrated that human T cells, recovered from these hu-PBL-BALB mice within 1 month posttransplant, proliferated and expressed activation markers upon stimulation with anti-CD3 monoclonal antibody. A vigorous antiallogeneic human cytotoxic T-lymphocyte (CTL) response could be generated in these mice by immunizing them with irradiated allogeneic cells. Moreover, anti-human immunodeficiency virus type 1 (HIV-1) Net-specific human CTLs could be generated in vivo from naive lymphocytes by immunization of mouse-human chimeras with a recombinant vaccinia-nef virus. This model may be used to evaluate potential immunomodulatory drugs or cytokines, and could provide a relevant model for testing HIV vaccines, for production of antiviral T-cell clones for adoptive therapy, and for studying human T-cell responses in vivo.
Segall
H
H
Department of Membrane Research and Biophysics, Weizmann Institute of Science, Rehovot, Israel.
Lubin
I
I
Marcus
H
H
Canaan
A
A
Reisner
Y
Y
D016915:AIDS Vaccines / Q000276:immunology; D000818:Animals; D016026:Bone Marrow Transplantation; D002051:Burkitt Lymphoma / Q000276:immunology / Q000473:pathology; D003602:Cytotoxicity, Immunologic; D015693:Gene Products, nef / Q000276:immunology*; D006084:Graft Rejection / Q000276:immunology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007114:Immunization; D016219:Immunotherapy, Adoptive; D007274:Injections, Intraperitoneal; D007519:Isoantigens / Q000276:immunology*; D008213:Lymphocyte Activation; D051379:Mice; D008807:Mice, Inbred BALB C; D016513:Mice, SCID / Q000276:immunology*; D016853:Muromonab-CD3 / Q000276:immunology; D009368:Neoplasm Transplantation / Q000276:immunology; D011828:Radiation Chimera / Q000276:immunology*; D015375:Receptors, Interleukin-2 / Q000032:analysis; D013601:T-Lymphocytes / Q000637:transplantation*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014183:Transplantation, Heterologous / Q000276:immunology*; D014184:Transplantation, Homologous; D014407:Tumor Cells, Cultured; D014614:Vaccines, Synthetic / Q000276:immunology; D014616:Vaccinia virus / Q000276:immunology; D054311:nef Gene Products, Human Immunodeficiency Virus
D016915:AIDS Vaccines; D015693:Gene Products, nef; D007519:Isoantigens; D016853:Muromonab-CD3; D015375:Receptors, Interleukin-2; D014614:Vaccines, Synthetic; D054311:nef Gene Products, Human Immunodeficiency Virus